InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by Stuart Iain, Directeur Scientifique. Officer active across 1 companies, notably VYNE Therapeutics Inc.. Aggregated, 10 disclosures have been published. The latest transaction was filed on 31 March 2022 — Retenue fiscale. Regulator: SEC (Form 4). The full history is openly available.
Declarations10 total
€2,0363,469 shares@ €0.5870.011% mcap7.8% of flow
Common Stock
SEC:0001209191-22-022530:0·
075,000 shares0
Common Stock
SEC:0001209191-22-020066:0·
€1,1261,250 shares@ €0.90070.0058% mcap9.4% of flow
Common Stock
SEC:0001209191-22-000858·
€1,1261,250 shares@ €0.90070.0058% mcap4.3% of flow
Common Stock
SEC:0001209191-22-000858:0·
€1,7771,480 shares@ €1.20090.0092% mcap14.8% of flow
Common Stock
SEC:0001209191-21-058519·
€1,7771,480 shares@ €1.20090.0092% mcap6.8% of flow
Common Stock
SEC:0001209191-21-058519:0·
060,859 shares0
Common Stock
SEC:0001209191-21-054836·
060,859 shares0
Common Stock
SEC:0001209191-21-054836:0·
€9,1273,083 shares@ €2.96030.047% mcap75.9% of flow
Common Stock
SEC:0001209191-21-044979·
€9,1273,083 shares@ €2.96030.047% mcap35.0% of flow
Common Stock
SEC:0001209191-21-044979:0·
10 of 10 declarations
About Stuart Iain
Iain Stuart is the Chief Scientific Officer at VYNE Therapeutics Inc. In this role, he is responsible for leading the company's scientific and research initiatives. Stuart brings valuable expertise in biotechnology and drug development, contributing to innovation in healthcare. His commitment to improving treatments and patient care is essential in guiding VYNE's projects. He collaborates with research teams to ensure the success of clinical trials and the development of new treatments.
